and because my annual #dermatology appointment also had to be this week i just went for a #skin checkup and oh wonder i now have 24 additional holes burnt into me 🧀 
i need to stay out of the #sun altogether just can't afford her hickeys anymore
related #fuckcancer including #carcinomas
edit: not all were #carcinoma but still too many
Il carcinoma cutaneo sembrava imbattibile negli stadi avanzati. Poi due farmaci insieme hanno cambiato tutto: i pazienti ora vivono senza peggioramenti per 11 mesi invece di 3. Una scoperta che trasforma la disperazione in speranza concreta per migliaia di malati
#carcinoma #medicina #futuroprossimo
https://www.futuroprossimo.it/2025/06/carcinoma-cutaneo-doppia-terapia-quadruplica-sopravvivenza/
This #InsightsIntoImaging study by Jiangdian Song et al. proposes a pre-therapy PET/CT image-based #DeepLearning approach aimed at improving the #survival benefit and #clinical management of patients with esophageal squamous cell #carcinoma (ESCC).
Objectives The clinical decision-making regarding choosing surgery alone (SA) or surgery followed by postoperative adjuvant chemotherapy (SPOCT) in esophageal squamous cell carcinoma (ESCC) remains controversial. We aim to propose a pre-therapy PET/CT image-based deep learning approach to improve the survival benefit and clinical management of ESCC patients. Methods This retrospective multicenter study included 837 ESCC patients from three institutions. Prognostic biomarkers integrating six networks were developed to build an ESCC prognosis (ESCCPro) model and predict the survival probability of ESCC patients treated with SA and SPOCT. Patients who did not undergo surgical resection were in a control group. Overall survival (OS) was the primary end-point event. The expected improvement in survival prognosis with the application of ESCCPro to assign treatment protocols was estimated by comparing the survival of patients in each subgroup. Seven clinicians with varying experience evaluated how ESCCPro performed in assisting clinical decision-making. Results In this retrospective multicenter study, patients receiving SA had a median OS 9.2 months longer than controls. No significant differences in survival were found between SA patients with predicted poor outcomes and the controls (p > 0.05). It was estimated that if ESCCPro was used to determine SA and SPOCT eligibility, the median OS in the ESCCPro-recommended SA group and SPOCT group would have been 15.3 months and 24.9 months longer, respectively. In addition, ESCCPro also significantly improved prognosis accuracy, certainty, and the efficiency of clinical experts. Conclusion ESCCPro assistance improved the survival benefit of ESCC patients and the clinical decision-making among the two treatment approaches. Critical relevance statement The ESCCPro model for treatment decision-making is promising to improve overall survival in ESCC patients undergoing surgical resection and patients undergoing surgery followed by postoperative adjuvant chemotherapy. Key Points ESCC is associated with a poor prognosis and unclear ideal treatments. ESCCPro predicts the survival of patients with ESCC and the expected benefit from SA. ESCCPro improves clinicians’ stratification of patients’ prognoses. Graphical Abstract
RAKESH M. SINGH
Heliograph
Scientific Frontline
All Scientifical
Alexander J. Stein
Futuro Prossimo 
El Pregoner del Metall
Science Updates
Insights Into Imaging